(Q34993830)

5 August 2017

1 reference

title

CYP2D6 and tamoxifen: DNA matters in breast cancer (English)

1 reference

5 August 2017

1 reference

1 reference

Janelle M Hoskins

1

1 reference

5 August 2017

Lisa A Carey

series ordinal

2

1 reference

5 August 2017

Howard L McLeod

series ordinal

3

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

5 August 2017

Nature Reviews Cancer

1 reference

5 August 2017

9

1 reference

5 August 2017

576-586

1 reference

5 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2683

5 August 2017

0 references

cites work

Pharmacogenomics--drug disposition, drug targets, and side effects

1 reference

Moving towards individualized medicine with pharmacogenomics

31 March 2020

1 reference

Global cancer statistics, 2002

31 March 2020

1 reference

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

31 March 2020

1 reference

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

31 March 2020

1 reference

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

31 March 2020

1 reference

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

31 March 2020

1 reference

International Union of Pharmacology. LXIV. Estrogen receptors

31 March 2020

1 reference

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

31 March 2020

1 reference

Tamoxifen in the treatment of breast cancer

31 March 2020

1 reference

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

31 March 2020

1 reference

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

31 March 2020

1 reference

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

31 March 2020

1 reference

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

31 March 2020

1 reference

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

31 March 2020

1 reference

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

31 March 2020

1 reference

Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants

31 March 2020

1 reference

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

31 March 2020

1 reference

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

31 March 2020

1 reference

Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.

31 March 2020

1 reference

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

31 March 2020

1 reference

Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen

31 March 2020

1 reference

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

31 March 2020

1 reference

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

31 March 2020

1 reference

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

31 March 2020

1 reference

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

31 March 2020

1 reference

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

31 March 2020

1 reference

Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

31 March 2020

1 reference

Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4.

31 March 2020

1 reference

Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases

31 March 2020

1 reference

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.

31 March 2020

1 reference

Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites

31 March 2020

1 reference

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

31 March 2020

1 reference

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

31 March 2020

1 reference

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.

31 March 2020

1 reference

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

31 March 2020

1 reference

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

31 March 2020

1 reference

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

31 March 2020

1 reference

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

31 March 2020

1 reference

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

31 March 2020

1 reference

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

31 March 2020

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

31 March 2020

1 reference

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

31 March 2020

1 reference

2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals

31 March 2020

1 reference

Development and trends of surgical modalities for breast cancer in China: a review of 16-year data

31 March 2020

1 reference

Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women

31 March 2020

1 reference

Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women

31 March 2020

1 reference

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

31 March 2020

1 reference

Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin

31 March 2020

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

31 March 2020

1 reference

Pharmacogenomics of tamoxifen and aromatase inhibitors.

31 March 2020

1 reference

Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer

31 March 2020

1 reference

Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen

31 March 2020

1 reference

Pharmacokinetics of selective estrogen receptor modulators

31 March 2020

1 reference

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

31 March 2020

1 reference

Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study

31 March 2020

1 reference

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

31 March 2020

1 reference

Identification of the primary gene defect at the cytochrome P450 CYP2D locus.

31 March 2020

1 reference

Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population.

31 March 2020

1 reference

Sequence-based CYP2D6 genotyping in the Korean population

31 March 2020

1 reference

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17

31 March 2020

1 reference

Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity

31 March 2020

1 reference

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis

31 March 2020

1 reference

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

31 March 2020

1 reference

Opportunities and strategies for breast cancer prevention through risk reduction

31 March 2020

1 reference

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

31 March 2020

1 reference

12 December 2020

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

1 reference

12 December 2020

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes

1 reference

12 December 2020

CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver

1 reference

12 December 2020

Cellular and molecular pharmacology of antiestrogen action and resistance

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2683

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference